Pharmacology

Action Mechanism of Action Reference
ANTISENSE INHIBITOR Bcl-2 mRNA antisense inhibitor PubMed PubMed PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Multiple Myeloma 3 D009101 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Carcinoma, Merkel Cell 2 D015266 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 D015464 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Small Cell Lung Carcinoma 2 D055752 ClinicalTrials
Gastrointestinal Stromal Tumors 2 D046152 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Colorectal Neoplasms 1 D015179 ClinicalTrials
Esophageal Neoplasms 1 D004938 ClinicalTrials
Head and Neck Neoplasms 1 D006258 ClinicalTrials
Waldenstrom Macroglobulinemia 1 D008258 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials
Kidney Neoplasms 1 D007680 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Ovarian Neoplasms 1 D010051 ClinicalTrials
Breast Neoplasms 1 D001943 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 1 D015451 ClinicalTrials
Breast Neoplasms, Male 1 D018567 ClinicalTrials
Lymphoma, Mantle-Cell 1 D020522 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL2109229
FDA SRS SH55B0RQ9K
PubChem 118984457